Facebook
Twitter
LinkedIn
Forward
Bispecific Antibodies in Cancer Care: Practical Guidance for the Multidisciplinary Team (Seattle)
Overview
This interactive, 2-hour CME/CE-certified symposium will equip the multidisciplinary oncology team with practical strategies for integrating bispecific antibodies into the care of patients with cancer. Through expert-led presentations, panel discussions, case examples, and audience engagement, participants will explore:
- Current and emerging bispecific therapies
- Strategies for toxicity mitigation and management
- Transitioning bispecific administration from inpatient to outpatient setting
The program aims to provide actionable insights for both academic and community-based cancer centers to address logistical, resourcing, and patient-care considerations to support the development of an outpatient clinic.
In this how-to session, learners will:
- Interact with national and local/regional experts in bispecific care
- Receive tips to streamline and avoid errors in the design of an outpatient bispecific clinic
- Fine-tune skills in the delivery of outpatient bispecifics
- Gain insights to expedite reimbursements for outpatient bispecifics
Learning Objectives
- Summarize the current clinical applications of bispecific antibodies in the treatment of patients with cancer.
- Discuss efficacy and expected outcomes with patients who are considering treatment with a bispecific antibody.
- Implement appropriate dosing and administration strategies for patients undergoing treatment with bispecific antibodies in the inpatient and outpatient settings.
- Anticipate treatment-related adverse events associated with bispecific antibody therapy.
Target Audience
This activity is designed to educate the multidisciplinary team including academic and community hematologists, oncologists, and hem/onc APPs, including nurse practitioners, physician assistants, pharmacists, and nurse specialists.
ATTENTION: This limited-seating event is open exclusively for clinicians actively practicing in oncology as well as those cancer center employees directly involved in the design and development of outpatient clinics where bispecifics are administered to patients. No pharmaceutical representatives will be seated for this event and their registrations will be declined. We thank you for your understanding.
This program is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Regeneron Pharmaceuticals, Inc.
Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email, mailing address, and payment information). This information is confidential and will only be used to contact you regarding your registration.
This program is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Regeneron Pharmaceuticals, Inc.
Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.
All Times Listed are for the Pacific Daylight Time Zone
Tuesday, May 6, 2025 | |
| 6:30pm | Welcome & Introductions |
| 6:40pm | Bispecific Antibodies: Past, Present, and Future » Ivan Huang, PharmD, BCOP |
| 6:55pm | Mitigation and Management of Bispecific Antibody–Associated Adverse Events » Laura Zitella, RN, MS, ACNP |
| 7:20pm | Panel Discussion: Anticipating Toxicities with Bispecific Antibody Therapy » Natasha Carrera, MHA (Moderator) » Binod Dhakal, MD, MS » Ivan Huang, PharmD, BCOP » Laura Zitella, RN, MS, ACNP |
| 7:35pm | Effective Implementation of Bispecific Antibodies » Binod Dhakal, MD, MS |
| 8:00pm | Panel Discussion: Operationalizing Bispecific Antibody Delivery » Natasha Carrera, MHA (Moderator) » Binod Dhakal, MD, MS » Ivan Huang, PharmD, BCOP » Laura Zitella, RN, MS, ACNP |
| 8:20pm | Key Takeaways and Final Audience Q&A |
Parking is free; there are several lots around the restaurant.
Faculty Presenters
Natasha Carrera, MHA
Associate Director, Service Line Management
Fred Hutchinson Cancer Center | UW Medicine
Seattle, WA
Natasha Carrera is a dedicated healthcare leader with over 20 years of experience in operations, clinical care, strategy, quality, and program development. She has a proven track record of driving innovation, enhancing patient care, and optimizing business performance within complex healthcare systems. Known for her ability to foster relationships, lead change, and develop high-value programs, she excels at delivering solutions that benefit both patients and stakeholders.
Binod Dhakal, MD, MS
Associate Professor of Medicine
Medical College of Wisconsin
Milwaukee, Wisconsin
Binod Dhakal, MD, MS, is Associate Professor of Medicine, at the Medical College of Wisconsin, Division of Hematology, specializing in multiple myeloma and plasma cell disorders. He graduated from Manipal College of Medical Sciences, Pokhara Nepal in 2004, completed Internal Medicine Residency at Saint Francis Hospital Evanston Illinois, and a fellowship in hematology/oncology at the Medical College of Wisconsin, where he also served as a Chief Fellow. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. His current research interests include myeloma immunotherapy focusing on the clinical and translational aspects, high risk myeloma and myeloma kidney disease.
Ivan Huang, PharmD, BCOP
Clinical Oncology Pharmacist
Fred Hutchinson Cancer Center | UW Medicine
Seattle, WA
Board-certified clinical oncology pharmacist specializing in malignant hematology and immunotherapy at the University of Washington Medical Center and Fred Hutchinson Cancer Center. He currently covers leukemia, lymphoma, multiple myeloma as well as immunotherapy clinics. He completed pharmacy school at University of Washington then completed PGY-1 pharmacy practice residency at MultiCare Good Samaritan Hospital and PGY-2 hematology/oncology residency at Cleveland Clinic. After residency training, he worked as an inpatient and ambulatory hematology/oncology and bone marrow transplant specialist at Oregon Health & Science University before his current role at Fred Hutchinson Cancer Center.
Laura Zitella, RN, MS, ACNP
Nurse Practitioner
Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC) Program at UCSF Health
San Francisco, CA
Laura J. Zitella is a hematology nurse practitioner in the Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC) Program at UCSF Health and is an Associate Clinical Professor in the Department of Physiological Nursing at the University of California San Francisco. She earned her Master of Science from the University of Illinois in Chicago. Laura holds certifications as an Acute Care Nurse Practitioner and an Advanced Oncology Certified Nurse. With more than 25 years of experience in oncology practice, Ms. Zitella is recognized as a national nurse practitioner leader. Her clinical expertise includes patients with hematologic malignancies receiving chemotherapy, immunotherapy, targeted therapy, investigational agents, hematopoietic cell transplantation, cellular therapy, and supportive care.
She is a prominent educator who has delivered hundreds of educational presentations to national and international audiences and authored numerous peer-reviewed publications, web courses, videos, and book chapters. She is a member of the Advanced Practitioner Society of Hematology and Oncology (APSHO), Advanced Practice Provider Oncology Summit planning committee, Association of Community Cancer Centers (ACCC), California Association of Nurse Practitioners (CANP), Oncology Nursing Society (ONS), Society of Hematologic Oncology (SOHO), and Society for Immunotherapy of Cancer (SITC).
Program Planning Commitee
Carrie Anne Graham, MSN, AOCNP
Carrie Anne Graham is an Advanced Registered Nurse Practitioner at Fred Hutch Cancer Center, specializing in hematology-oncology. She holds an AOCNP certification and currently sees patients in the undiagnosed tumor clinic. Additionally, she runs a separate procedures clinic where she performs cancer-related procedures, such as bone marrow biopsies and lumbar punctures. With 16 years of experience in neuro-oncology, Carrie brings extensive expertise to her role.
Carrie earned her Bachelor of Science in Nursing from Georgetown University and her Master of Science in Nursing from UCLA, specializing in adult oncology. She is the Director of the Fred Hutch Advanced Practice Oncology Fellowship and the Lead for the Fred Hutch Supportive Care APP program.
Carrie is dedicated to providing exceptional care, integrating the best healthcare practices to meet the unique needs of her patients. She emphasizes patient and family education, empowering them to make informed decisions for the best quality of life. Additionally, Carrie is passionate about mentoring new APPs, helping them build strong, meaningful careers in oncology.
Jeannine Sanford, ARNP, OCN
Co-Director of the Advanced Practice Provider program at Fred Hutch
Medical Director for Infusion Services and Acute Clinical Evaluation (ACE)
Fred Hutchinson Cancer Center | UW Medicine
Seattle, WA
Jeannine Sanford, ARNP, OCN is the Interim co-Director of the Advanced Practice Provider program at Fred Hutch and serves as Medical Director for Infusion Services and Acute Clinical Evaluation (ACE). She has worked in the urgent oncology setting since 2015, in both clinical and administrative roles. During this time, she has delivered presentations and partnered with health systems across the country on the development of oncology urgent care clinics and emerging best practices in the field of oncology. Her current responsibilities as Interim co-Director of APPs for the Fred Hutch include medical leadership and clinical oversight for APPs at all sites of care, strategic vision, workforce planning and utilization, development and training, and scope of practice. Jeannine is passionate about developing resources and educational initiatives which aid in the professional development of APPs.
Disclosures:
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Other Contributors
All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
Binod Dhakal, MD, MS discloses that he is a speaker for Johnson & Johnson, Sanofi and BristolMyersSquibb as well as on an advisory board for Johnson & Johnson, Karyopharm and Sanofi. Dr. Dhakal also is a consultant for Genentech and conducts research for Johnson & Johnson, Kite and Sanofi during the past 24 months.
Laura Zitella, NP discloses that she is on an advisory board for AbbVie and BristolMyersSquibb during the past 24 months.
Available Credit
- 2.00 ACPE PharmacyThe Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This conference is approved for up to 2.00 credit by the Washington State Pharmacy Association.
This activity is approved for up to 2.00 credit by the Washington State Pharmacy Association. ACPE#: 0130-9999-21--L01-P | Activity Type: Live| Start/End date: Tue, 05/06/2025 - 6:30pm-Tue, 05/06/2025 - 8:30pm The Washington State Pharmacy Association (WSPA) is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. NOTE FOR PHARMACISTS: It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP eProfile ID and DOB (in MMDD format)] within the evaluation, in order to receive credit for participating in this CPE activity. Following the activity’s end date, there is a maximum of 60 days allowed to upload the CPE information to the CPE Monitor. WSPA will upload the CPE information to the CPE monitor 50 days after the activity - please check your CPE Monitor at this time to ensure the CPE is uploaded in your profile. If you encounter any CPE problems, please contact WSPA at 425- 228-7171 - 2.00 AMA PRA Category 1 Credit™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this Live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 2.00 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 2.00 credit.
- 0.75 PharmacologyThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 0.75 credit.
Price
ATTENTION: This limited-seating event is open exclusively for clinicians actively practicing in oncology as well as those cancer center employees directly involved in the design and development of outpatient clinics where bispecifics are administered to patients. No pharmaceutical representatives will be seated for this event and their registrations will be declined. We thank you for your understanding.